Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR444245 (THOR-707) in combination therapies for head and neck squamous cell carcinoma
2021-002105-99Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegenzileukin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sanofi. Primary endpoint: Objective response rate (ORR). Started Sep 2021; status: terminated.
02
Drugs
pegenzileukin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2021-002105-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002105-99.